88 related articles for article (PubMed ID: 31937615)
1. A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
Berenson JR; To J; Spektor TM; Martinez D; Turner C; Sanchez A; Ghermezi M; Eades BM; Swift RA; Schwartz G; Eshaghian S; Stampleman L; Moss RA; Lim S; Vescio R
Clin Cancer Res; 2020 May; 26(10):2346-2353. PubMed ID: 31937615
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
Berenson JR; Limon A; Rice S; Safaie T; Boccia R; Yang H; Moezi M; Lim S; Schwartz G; Eshaghian S; Brobeck M; Swift R; Eades BM; Bujarski S; Sebhat Y; Ray R; Kim S; Del Dosso A; Vescio R
Target Oncol; 2024 May; 19(3):343-357. PubMed ID: 38643346
[TBL] [Abstract][Full Text] [Related]
3. Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea.
Lee HK; Jang HY; Kim IW; Oh JM
J Cancer Res Clin Oncol; 2024 May; 150(5):266. PubMed ID: 38769166
[TBL] [Abstract][Full Text] [Related]
4. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Lee HC; Ramasamy K; Macro M; Davies FE; Abonour R; van Rhee F; Hungria VTM; Puig N; Ren K; Silar J; Enwemadu V; Cherepanov D; Leleu X
Eur J Haematol; 2024 Apr; ():. PubMed ID: 38654611
[TBL] [Abstract][Full Text] [Related]
5. A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.
Paul B; Liedtke M; Khouri J; Rifkin R; Gandhi MD; Kin A; Levy MY; Silbermann R; Cottini F; Sborov DW; Sandhu I; Villarreal L; Murphy M; Gu L; Chen A; Rajakumaraswamy N; Usmani SZ
Future Oncol; 2023 Jan; 19(1):7-17. PubMed ID: 36779512
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis.
van Nieuwenhuijzen N; Frunt R; May AM; Minnema MC
Blood Cancer J; 2021 Mar; 11(3):44. PubMed ID: 33649328
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Palladini G; Kastritis E; Maurer MS; Zonder J; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Bumma N; Kaufman JL; Medvedova E; Kovacsovics T; Rosenzweig M; Sanchorawala V; Qin X; Vasey SY; Weiss BM; Vermeulen J; Merlini G; Comenzo RL
Blood; 2020 Jul; 136(1):71-80. PubMed ID: 32244252
[TBL] [Abstract][Full Text] [Related]
8. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.
Ogiya D; Liu J; Ohguchi H; Kurata K; Samur MK; Tai YT; Adamia S; Ando K; Hideshima T; Anderson KC
Blood; 2020 Nov; 136(20):2334-2345. PubMed ID: 32844992
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.
Lentzsch S; Lagos GG; Comenzo RL; Zonder JA; Osman K; Pan S; Bhutani D; Pregja S; Sanchorawala V; Landau H
J Clin Oncol; 2020 May; 38(13):1455-1462. PubMed ID: 32083996
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Laubach JP; Schjesvold F; Mariz M; Dimopoulos MA; Lech-Maranda E; Spicka I; Hungria VTM; Shelekhova T; Abdo A; Jacobasch L; Polprasert C; Hájek R; Illés Á; Wróbel T; Sureda A; Beksac M; Gonçalves IZ; Bladé J; Rajkumar SV; Chari A; Lonial S; Spencer A; Maison-Blanche P; Moreau P; San-Miguel JF; Richardson PG
Lancet Oncol; 2021 Jan; 22(1):142-154. PubMed ID: 33301738
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.
Durie BGM; Kumar SK; Usmani SZ; Nonyane BAS; Ammann EM; Lam A; Kobos R; Maiese EM; Facon T
Am J Hematol; 2020 Dec; 95(12):1486-1494. PubMed ID: 32804408
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Jasielec JK; Kubicki T; Raje N; Vij R; Reece D; Berdeja J; Derman BA; Rosenbaum CA; Richardson P; Gurbuxani S; Major S; Wolfe B; Stefka AT; Stephens L; Tinari KM; Hycner T; Rojek AE; Dytfeld D; Griffith KA; Zimmerman TM; Jakubowiak AJ
Blood; 2020 Nov; 136(22):2513-2523. PubMed ID: 32735641
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma.
Shibayama H; Matsumoto M; Kosugi H; Shibayama K; Yamazaki H; Iida S
Int J Hematol; 2021 Jan; 113(1):112-121. PubMed ID: 32915384
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Terpos E; Ramasamy K; Maouche N; Minarik J; Ntanasis-Stathopoulos I; Katodritou E; Jenner MW; Plonkova H; Gavriatopoulou M; Vallance GD; Pika T; Kotsopoulou M; Kothari J; Jelinek T; Kastritis E; Aitchison R; Dimopoulos MA; Zomas A; Hajek R
Ann Hematol; 2020 May; 99(5):1049-1061. PubMed ID: 32236735
[TBL] [Abstract][Full Text] [Related]
15. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.
Vij R; Nath R; Afar DEH; Mateos MV; Berdeja JG; Raab MS; Guenther A; Martínez-López J; Jakubowiak AJ; Leleu X; Weisel K; Wong S; Gulbranson S; Sheridan JP; Reddy A; Paiva B; Singhal A; San-Miguel JF; Moreau P
Clin Cancer Res; 2020 May; 26(10):2308-2317. PubMed ID: 31969330
[TBL] [Abstract][Full Text] [Related]
16. Anti-myeloma potential of ruxolitinib in co-existing JAK2V617F-positive smouldering myeloma and polycythaemia vera.
Lee H; McCulloch S; Mahe E; Shafey M; Rashid-Kolvear F; Khan F; Prajapati D; Neri P; Duggan P; Tay J; Bahlis N; Jimenez-Zepeda VH
Br J Haematol; 2020 May; 189(3):e114-e118. PubMed ID: 32080835
[No Abstract] [Full Text] [Related]
17. Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance.
Georgakopoulou R; Andrikopoulou A; Sergentanis TN; Fiste O; Zagouri F; Gavriatopoulou M; Psaltopoulou T; Kastritis E; Terpos E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):361-367. PubMed ID: 33582053
[TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity reaction to pegylated liposomal doxorubicin administration for Mullerian carcinoma in Japanese women.
Yamaguchi S; Yahata H; Okugawa K; Kodama K; Yagi H; Yasunaga M; Ohgami T; Onoyama I; Asanoma K; Kato K
J Obstet Gynaecol Res; 2021 Apr; 47(4):1544-1548. PubMed ID: 33501770
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Usmani SZ; Hoering A; Ailawadhi S; Sexton R; Lipe B; Hita SF; Valent J; Rosenzweig M; Zonder JA; Dhodapkar M; Callander N; Zimmerman T; Voorhees PM; Durie B; Rajkumar SV; Richardson PG; Orlowski RZ;
Lancet Haematol; 2021 Jan; 8(1):e45-e54. PubMed ID: 33357482
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]